154 related articles for article (PubMed ID: 30279972)
1. Correction: Checkpoint inhibitor induced cardiotoxicity: managing the drawbacks of our newest agents against cancer.
Brüstle K; Heidecker B
Oncotarget; 2018 Sep; 9(70):33440. PubMed ID: 30279972
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint inhibitor induced cardiotoxicity: managing the drawbacks of our newest agents against cancer.
Brüstle K; Heidecker B
Oncotarget; 2017 Dec; 8(63):106165-106166. PubMed ID: 29290934
[No Abstract] [Full Text] [Related]
3. Correction: A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.
Zhu J; Wang M; Yu Y; Qi H; Han K; Tang J; Zhang Z; Zeng Y; Cao B; Qiao C; Zhang H; Hou T; Mao X
Oncotarget; 2019 Dec; 10(65):7010-7011. PubMed ID: 31857854
[TBL] [Abstract][Full Text] [Related]
4. Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix.
Mann M; Kumar S; Chauhan SS; Bhatla N; Kumar S; Bakhshi S; Gupta R; Sharma A; Kumar L
Oncotarget; 2019 Jul; 10(46):4802. PubMed ID: 31413820
[TBL] [Abstract][Full Text] [Related]
5. Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Robb CM; Kour S; Contreras JI; Agarwal E; Barger CJ; Rana S; Sonawane Y; Neilsen BK; Taylor M; Kizhake S; Thakare RN; Chowdhury S; Wang J; Black JD; Hollingsworth MA; Brattain MG; Natarajan A
Oncotarget; 2020 Jun; 11(25):2462-2463. PubMed ID: 32637035
[TBL] [Abstract][Full Text] [Related]
6. Correction: Neuroprotective effects of bajijiasu against cognitive impairment induced by amyloid-β in APP/PS1 mice.
Cai H; Wang Y; He J; Cai T; Wu J; Fang J; Zhang R; Guo Z; Guan L; Zhan Q; Lin L; Xiao Y; Pan H; Wang Q
Oncotarget; 2018 May; 9(39):25750. PubMed ID: 29877511
[TBL] [Abstract][Full Text] [Related]
7. Correction: COTI-2, a novel small molecule that is active against multiple human cancer cell lines
Salim KY; Vareki SM; Danter WR; San-Marina S; Koropatnick J
Oncotarget; 2017 Sep; 8(36):60724. PubMed ID: 29062467
[TBL] [Abstract][Full Text] [Related]
8. Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Kim S; Tiedt R; Loo A; Horn T; Delach S; Kovats S; Haas K; Engstler BS; Cao A; Pinzon-Ortiz M; Mulford I; Acker MG; Chopra R; Brain C; Tomaso ED; Sellers WR; Caponigro G
Oncotarget; 2020 Apr; 11(14):1289. PubMed ID: 32292577
[TBL] [Abstract][Full Text] [Related]
9. Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Hideshima T; Mazitschek R; Qi J; Mimura N; Tseng JC; Kung AL; Bradner JE; Anderson KC
Oncotarget; 2021 Aug; 12(17):1736. PubMed ID: 34434504
[TBL] [Abstract][Full Text] [Related]
10. Correction: Halofuginone inhibits radiotherapy-induced epithelial-mesenchymal transition in lung cancer.
Chen Y; Liu W; Wang P; Hou H; Liu N; Gong L; Wang Y; Ji K; Zhao L; Wang P
Oncotarget; 2018 Aug; 9(60):31787. PubMed ID: 30167094
[TBL] [Abstract][Full Text] [Related]
11. Correction:
Holien T; Misund K; Olsen OE; Baranowska KA; Buene G; Børset M; Waage A; Sundan A
Oncotarget; 2018 Nov; 9(89):36048. PubMed ID: 30542518
[TBL] [Abstract][Full Text] [Related]
12. Correction: Colon cancer-induced interleukin-35 inhibits betacatenin- mediated pro-oncogenic activity.
Jiang Y; Ma Y; Li R; Sun J
Oncotarget; 2018 Aug; 9(60):31788. PubMed ID: 30167095
[TBL] [Abstract][Full Text] [Related]
13. Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.
Lee HJ; Lee J; Jeong P; Choi J; Baek J; Ahn SL; Moon Y; Heo JD; Choi YH; Chin YW; Kim YC; Han SY
Oncotarget; 2018 Apr; 9(28):20219. PubMed ID: 29733074
[TBL] [Abstract][Full Text] [Related]
14. Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity
Shi F; Zhang J; Liu H; Wu L; Jiang H; Wu Q; Liu T; Lou M; Wu H
Oncotarget; 2018 Mar; 9(24):17255. PubMed ID: 29683149
[TBL] [Abstract][Full Text] [Related]
15. Correction: Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents.
Gaston J; Cheradame L; Yvonnet V; Deas O; Poupon MF; Judde JG; Cairo S; Goffin V
Oncotarget; 2019 Jun; 10(41):4249-4251. PubMed ID: 31289622
[TBL] [Abstract][Full Text] [Related]
16. Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.
Hu Z; Hu Y; Liu X; Xi R; Zhang A; Liu D; Xie Q; Chen L
Oncotarget; 2018 Oct; 9(81):35283. PubMed ID: 30443295
[TBL] [Abstract][Full Text] [Related]
17. Correction: Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.
Ahmed MA; Selzer E; Dörr W; Jomrich G; Harpain F; Silberhumer GR; Müllauer L; Holzmann K; Grasl-Kraupp B; Grusch M; Berger W; Marian B
Oncotarget; 2019 Sep; 10(51):5385-5386. PubMed ID: 31555396
[TBL] [Abstract][Full Text] [Related]
18. Correction: Sirt3-mediated mitophagy protects tumor cells against apoptosis under hypoxia.
Qiao A; Wang K; Yuan Y; Guan Y; Ren X; Li L; Chen X; Li F; Chen AF; Zhou J; Yang JM; Cheng Y
Oncotarget; 2018 Jun; 9(43):27318. PubMed ID: 29930768
[TBL] [Abstract][Full Text] [Related]
19. Correction: Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis.
Shin EA; Sohn EJ; Won G; Choi JU; Jeong M; Kim B; Kim MJ; Kim SH
Oncotarget; 2018 Jul; 9(55):30720. PubMed ID: 30093981
[TBL] [Abstract][Full Text] [Related]
20. Correction: Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
Chung S; Kijima K; Kudo A; Fujisawa Y; Harada Y; Taira A; Takamatsu N; Miyamoto T; Matsuo Y; Nakamura Y
Oncotarget; 2020 Oct; 11(41):3749-3750. PubMed ID: 33110482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
